Capecitabine
- Generic Name
- Capecitabine
- Brand Names
- Ecansya, Xeloda, Capecitabine Medac, Ecansya (previously Capecitabine Krka), Capecitabine Accord, Capecitabine Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C15H22FN3O6
- CAS Number
- 154361-50-9
- Unique Ingredient Identifier
- 6804DJ8Z9U
- Background
Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
- Indication
Capecitabine is indicated as treatment for a variety of cancer types. For colorectal cancer, capecitabine is indicated as a single agent or a component of a combination chemotherapy regiment for the adjuvant treatment of stage III colon cancer and treatment unresectable or metastatic colorectal cancer. It can also be used as a part of a combination chemotherapy perioperative treatment of adult locally advanced rectal cancer. For breast cancer, capecitabine is indicated for advanced or metastatic breast cancer as a single agent if an anthracycline- or taxane-containing chemotherapy is not indicated or as a regimen with docetaxel after disease progression on prior anthracycline-containing chemotherapy. For gastric, esophageal, or gastroesophageal junction (GEJ) cancer, capecitabine is indicated as a component of a combination chemotherapy treatment for the treatment of adult unresectable or metastatic gastric, esophageal, or GEJ cancer or adult HER2-overexpressing metastatic gastric or GEJ adenocarcinoma who have not received prior treatment for metastatic disease. Finally, for pancreatic cancer, capecitabine is indicated as adjuvant treatment for adult pancreatic adenocarcinoma as a component of a combination chemotherapy regimen.
- Associated Conditions
- Advanced or Metastatic Breast Cancer, Carcinoma of Gallbladder, Cholangiocarcinoma, Hepatocellular Carcinoma, Locally Advanced Rectal Cancer (LARC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Gastric Cancers, Metastatic Neuroendocrine Tumors, Pancreatic Adenocarcinoma, Pancreatic Cancer, Advanced or Metastatic, Platinum-resistant Epithelial Ovarian Cancer, Refractory Fallopian Tube Carcinoma, Stage III Colon Cancer, Unresectable or Metastatic Colorectal Cancer, Metastatic pancreatic endocrine carcinoma, Refractory peritoneal cancer, Refractory, metastatic Colorectal carcinoma, Unresectable, metastatic Esophageal Cancer, Unresectable, metastatic Gastric Cancer, Unresectable, metastatic Gastroesophageal Junction Cancer
- Associated Therapies
- Chemotherapy
Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients With Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-12-20
- Last Posted Date
- 2024-06-17
- Lead Sponsor
- Aston Sci. Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT05163223
- Locations
- 🇺🇸
Ironwood Cancer and Research Centers, Chandler, Arizona, United States
🇺🇸Scripps Health, La Jolla, California, United States
🇨🇳China Medical University Hospital, Taichung City, Taiwan
A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers
- First Posted Date
- 2021-12-09
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 918
- Registration Number
- NCT05152147
- Locations
- 🇦🇷
Hospital de Gastroenterología Dr Bonorino Udaondo, Buenos Aires, Argentina
🇦🇷Fundación Centro de Medicina Nuclear y Molecular ER, Córdoba, Argentina
🇦🇷Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
A Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)
- Conditions
- Interventions
- First Posted Date
- 2021-12-03
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- Ono Pharmaceutical Co. Ltd
- Target Recruit Count
- 626
- Registration Number
- NCT05144854
- Locations
- 🇨🇳
National Cheng Kung University Hospital, Tainan, Taiwan
🇨🇳Taichung Veterans General Hospital, Taichung, Taiwan
🇯🇵IMSUT Hospital, The Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo, Japan
Preoperative Chemoradiotherapy With CApecitabine and Temozolomide in MGMT Silenced, MSS, Locally Advanced RecTal Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-11-29
- Last Posted Date
- 2023-03-01
- Target Recruit Count
- 21
- Registration Number
- NCT05136326
- Locations
- 🇮🇹
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Neoadjuvant Treatment of Breast Cancer
- First Posted Date
- 2021-11-23
- Last Posted Date
- 2021-11-23
- Lead Sponsor
- National Institute of Oncology, Hungary
- Target Recruit Count
- 300
- Registration Number
- NCT05131893
- Locations
- 🇭🇺
National Institute of Oncolgy, Budapest, Hungary
Camrelizumab Plus Pyrotinib Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
- First Posted Date
- 2021-11-08
- Last Posted Date
- 2021-11-08
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 65
- Registration Number
- NCT05111444
- Locations
- 🇨🇳
270 Dongan Road, Fudan University Shanghai Cancer Center, Shanghai, China
Adaptive Radiation for Locally Advanced Rectal Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2021-11-05
- Last Posted Date
- 2024-12-06
- Target Recruit Count
- 20
- Registration Number
- NCT05108428
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)
- Conditions
- Interventions
- First Posted Date
- 2021-11-03
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 732
- Registration Number
- NCT05104866
- Locations
- 🇬🇧
Research Site, Truro, United Kingdom
A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers
- First Posted Date
- 2021-10-25
- Last Posted Date
- 2022-08-18
- Lead Sponsor
- Silverback Therapeutics
- Target Recruit Count
- 2
- Registration Number
- NCT05091528
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Anrotinib in Combination With Capecitabine in Advanced Triple Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-10-22
- Last Posted Date
- 2022-01-10
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 35
- Registration Number
- NCT05089643
- Locations
- 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, China
🇨🇳Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.